AU656965B2 - Detection of DNA/RNA by fluorescence polarization - Google Patents
Detection of DNA/RNA by fluorescence polarization Download PDFInfo
- Publication number
- AU656965B2 AU656965B2 AU16904/92A AU1690492A AU656965B2 AU 656965 B2 AU656965 B2 AU 656965B2 AU 16904/92 A AU16904/92 A AU 16904/92A AU 1690492 A AU1690492 A AU 1690492A AU 656965 B2 AU656965 B2 AU 656965B2
- Authority
- AU
- Australia
- Prior art keywords
- probe
- nucleic acids
- amplified
- sequence
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000002875 fluorescence polarization Methods 0.000 title claims description 34
- 238000001514 detection method Methods 0.000 title description 19
- 239000000523 sample Substances 0.000 claims description 70
- 150000007523 nucleic acids Chemical class 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 53
- 108020004707 nucleic acids Proteins 0.000 claims description 43
- 102000039446 nucleic acids Human genes 0.000 claims description 43
- 238000009396 hybridization Methods 0.000 claims description 31
- 108091034117 Oligonucleotide Proteins 0.000 claims description 26
- 230000000295 complement effect Effects 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 239000000872 buffer Substances 0.000 claims description 13
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 13
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 9
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 9
- 239000002853 nucleic acid probe Substances 0.000 claims description 9
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 8
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 7
- 238000000137 annealing Methods 0.000 claims description 7
- 239000002751 oligonucleotide probe Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 4
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 4
- 229940104302 cytosine Drugs 0.000 claims description 4
- 229940029575 guanosine Drugs 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- MCNLTUITFWBDSX-UHFFFAOYSA-N 4-chlorotriazin-5-amine Chemical compound NC1=CN=NN=C1Cl MCNLTUITFWBDSX-UHFFFAOYSA-N 0.000 claims 1
- 102100034343 Integrase Human genes 0.000 claims 1
- 230000003321 amplification Effects 0.000 description 23
- 238000003199 nucleic acid amplification method Methods 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 20
- 241000725303 Human immunodeficiency virus Species 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000013615 primer Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 8
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 102100031780 Endonuclease Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000010287 polarization Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical class O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- HWQQCFPHXPNXHC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 HWQQCFPHXPNXHC-UHFFFAOYSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 101100322030 Drosophila melanogaster Abl gene Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- -1 aminochlorotriazinylaminoethylphosphoryl group Chemical group 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 102000006481 HIV Receptors Human genes 0.000 description 2
- 108010083930 HIV Receptors Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Description
:i i 1.: OPI DATE 17/11/92 APPLN. ID 16904/92 III llll III Illllllll AOJP DATE 14./11/92 PCT NUMBER PCT/US92/02983 I u 111111 AU9216904 INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 5 (11) International Publication Number: WO 92/18650 C12Q 1/68, CO7H 15/12 Al C12N 15/00 (43) International Publication Date: 29 October 1992 (29.10.92) (21) International Application Number: PCT/US92/02983 (74)Agents: BARTA, Kent, S. et al.; One Baxter Parkway, Deerfield, IL 60015 (US).
(22) International Filing Date: 10 April 1992 (10.04.92) (81) Designated States: AT (European patent), AU, BE (Euro- Priority data: pean patent), CA, CH (European patent), DE (Euro- 683,923 11 April 1991 (11.04.91) US pean patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (Euro- (71) Applicant: BAXTER DIAGNOSTICS INC. [US/US]; pean patent), MC (European patent), NL (European pa- One Baxter Parkway, Deerfield, IL 60015 tent), SE (European patent).
(72) Inventors: WANG, Chao-huei, Jeffrey 5040 Fox Lane, Gurnee, IL 60031 AMMONS, Harryl, C. 1301 Published Georgia Street, Gary, IN 46407 JOLLEY, Michael, With international search report.
E. 34469 North Circle Drive, Round Lake, IL 60073
(US).
C 56965 (54) Title: DETECTION OF DNA/RNA BY FLUORESCENCE POLARIZATION (57) Abstract A homogeneous method for detecting amplified RNA or DNA target sequences utilizes signal-labelled DNA or RNA probes which show detectably increased fluor..scence polarization w,n hybridized to target sequences. A convenient one-step analytical procedure requiring no nucleic acid extraction or signal separation step is thereby provided.
WO 92/18650 PCT/US92/02983 1 DETECTION OF DNA/RNA BY FLUORESCENCE POLARIZATION This application Is &-ent-inuation-in-part co-pending application m er 7/430,844 filed Field of the Invention The present invention relates to the field of detecting target nucleic acid sequences contained in complex biological mixtures. More particularly, the invention relates to detection of nucleic acid sequences originally present in such mixtures in extremely low concentrations, by first enzymatically amplifying the specific target sequences, and then detecting them in a substantially homogeneous assay utilizing fluorescence polarization. An increase in fluorescence polarization indicates the extent of hybridization of a probe with the amplified target sequences.
Background of the Invention Inthe study of cell populations associated with disease states it is frequently found that only a subpopulation of available susceptible cells actually exhibit the morbid phenotype. In infectious diseases, the proportions of cells which are passively or actively infected may be very low, and the disease caused by the infectious agent may go unnoticed clinically even though an infected individual can transmit the agent to others. Examples of such infectious agents are clammy, protozoans, certain bacteria, and many viruses.
Amongst viruses, the human immunodeficiency virus (HIV) is known to have an extremely long latent period before the onset of the clinical symptoms knowi as AIDS. Latency may extend to several years during which the infected individual is capable of transmitting the virus to others through intimate contact, sharing of WO 92/18650 PCT/US92/02983 2 intravenous injection apparatus, or through donation of blood products.
HIV infection is specific for thymus-derived lymphocytes (T cells), and in particular the subset T cells having immune helper function. These T cells possess highly specific HIV receptors on their surfaces to which the virus attaches to gain entry to the cell.
Monolingual antibodies, grouped generally in the CD4 cluster, see Leukocyte Typing III, Ed. A.J. McMichael, Oxford University Press, 1987, and specific for the HIV receptor, have been isolated heretofore (see Kung et al., U.S. Patent No. 4,381,295). A signal molecule can be attached to such antibodies which binds selectively to those cells expressing the receptor antigen thereby identifying the helper T cell subpopulation.
Quantitation of cell numbers of such lymphocyte subpopulations may conveniently be carried out in a flow cytometer.
In normal individuals approximately 50 percent of peripheral T cells are helper cells. In HIV infected patients, this proportion declines sharply because the virus is cytotoxic to helper T cells. In latent infections or early in the course of clinical disease, the proportion of the helper T cell population actually containing virus, in either lytic or latent phase, may be very low, even to the order of 1 to 1000. This means that in such patients, a 2 ml sample of blood may contain only one or a few copies of the virus or its genome. At his stage of infection, no antibodies to viral proteins can be detected, even with the most sensitive immunological techniques available. There is a great danger that individuals at such early stages of infection may transmit the virus in donated blood without the virus being detected by conventional screening methods.
WO 92/18650 PCT/US92/02983 3 The most sensitive immunological techniques are capable of detecting antibody by HIV at minimally 21 days post-infection. A variety of immunoassays for detection of HIV have been described including enzymelinked immunoassays (ELISA), immunodiffusion assays, radioimmunoassays (RIA), and the classical Western blot. Also a number of distinct assay strategies have been developed. One group of assays utilizes HIV viral antigens, particularly viral protein containing epitopes in conserved domains, bound covalently to a solid matrix. The matrix-bound enzyme is contacted with a serum sample, and any anti-antigen antibodies contained therein bind to antigen. In the typical sandwich assay, antiserum raised in a heterologous species against human antibody antigens conjugated to an enzyme (ELISA), fluorescent molecule, or other signal generating substance, is then reacted with the washed matrix-bound antigen-anti-antigen complex. The signal emitted by the signal generating substance is typically a chromophor, fluorescent signal, beta or gamma radiation, or other such measurable emission.
Alternatively, analysis of serum antibodies maybe obtained by Western blot consisting of gel electrophoresis of viral proteins, electrotransfer of the proteins to blotting paper, followed by reaction with antisera, and color development of the individual protein bands. The Western blot analysis is employed on a confirming test by blood banks in blood screening procedures. For a general review of the various immunological methods available, see Stites et al., Basic Clinical Immunology, Appleton Lange, 1987.
There have been many attempts in the prior art to make detection of serum antibodies to HIV or other low concentration targets more sensitive and selective.
The two major approaches have been target amplification I WOf 92185 PC'rUS92029 WO 92/18650 P~7rUS92/02983 WO 92/18650 PCT/US92/02983 4 and signal amplification. In signal amplification, the object is to couple a very low level signal event to a large number of subsequent secondary signals which can be detected and quantified. It is apparent that this coupling must be highly specific so that background secondary signals do not proportionally increase. One such signal amplification system takes advantage of the extremely high affinity of avidin for biotin. A large number of biotin molecules can be covalently coupled to an antibody specific for viral antigens. When reacted with fluorochome-coupled avidin a large complex is formed having unusually brilliant fluorescence.
Another system utilizes a mixture of monoclonal antibodies conjugated to a signal generating substance, each individual antibody type being specific for a different structurally distinct epitope. The theory is that a greater number of signal generating antibody molecules will bind to antigen if there are no overlapping specificities.
Another approach is to target nucleic acid sequences of the virus with a homologous nucleic acid probe coupled to a signal amplification system. Under renaturing conditions the viral RNA (or denatured DNA) anneals to the complementary sequence of an oligonucleotide probe. Detection of the hybrid is afforded by signal generating substances covalently conjugated to the probe. Applicable to his approach are the enzyme proteolyzes a zymogen which then acts upon a substrate to generate a measurable signal. Many of the variations in such techniques are described in Lelie et al., Detection of HIV Infection Using Second- Generation HIV Assay, IV International AIDS Symposium, Stockholm, 1988.
The second major approach involves target amplification in which the target interacting with the WO 92/18650 PCT/US92/02983 WO 92/18650 PCT/US92/02983 signal-generating entity is itself multiplied in number. Since proteins cannot replicate, target amplification inherently requires a nucleic acid sequence, and an enzymatic system which can replicate the target sequence in vitro. One such target amplification technique is disclosed in U.S. Patent Nos. 4,683,195 (Mullis et al.) and 4,683,202 (Mullis), and is called polymerase chain reaction (PCR) amplification.
In PCR, a mixture of nucleic acids containing a DNA sequence in a small quantity is heated to denature double stranded DNA. Primers consisting of a oligonucleotide capable of mediating DNA synthesis from a single stranded template is added under conditions which favor annealing of the primers to their specific complementary sequences. A thermostable DNA polymerase is added, and an extension reaction proceeds at 72 0 C in the presence of deoxynucleotide triphosphates, adenosine triphosphate and cofactors. The reaction is run at high temperatures to avoid non-specific binding of primer to non-homologous sequences. Under these stringent conditions fidelity of polymerization to the desired sequences is very high.
After polymerization is complete, the mixture is again heated to denature the double stranded DNAs, and the extension reaction is repeated. Such repetition of extension polymerization may occur several times until the target sequence is amplified in numbers sufficient to detect by any of the signal-conjugated probe assays described hereinabove.
In a second target amplification scheme called TAS, a first primer oligonucleotide or oligonucleotide containing an RNA transcriptase promoter-binding sequence is annealed to the target sequence and extended by DNA polymerase or reverse transcriptase.
I I-- WO 92/18650 PCUI/US92/02983 6 Following melting, a second primer complementary to the newly formed oligomer in a region distal to the first primer binding sequence is added, annealed, and extended. The resultant duplex DNA oligomer thus has a sequence flanking the target region and containing a transcriptional promoter. Addition of RNA transcriptase, in the presence of oligonucleotide triphosphates, adenosine triphosphate, and cofactors institutes transcription in vitro yielding up to 1000 copies of the target sequence. The TAS methods have been disclosed in WO 88/01050 (Berg et al.).
In a variation of TAS, RNAse H is added to the reaction mix. RNAse H specifically catalyzes the stepwise hydrolysis of RNA bases in an RNA-DNA duplex, so that after a cDNA strand has been synthesized with reverse transcriptase the RNAse digests the RNA strand of the duplex to permit synthesis of the second complementary DNA strand by DNA polymerase. It will be apparent that since a heating step to melt the DNA-RNA duplex is unnecessary for cyclization of the reaction, the entire amplification can be performed in a single incubation. The disadvantages of the TAS and 3SR methods, compared to PCR is the lesser degree of stringency because of non-specific primer bonding at I 25 the lower temperature.
Finally, target amplification can be carried out in a ligase-mediated procedure. In this procedure, complementary primer sets form adjacent hybrids on both complementary strands of the target. Ligase then joins the primers together at the nick separation, after hybridization. The ligated double primer can then act as a template for further ligation of primers in a subsequent melting and rehybridization step.
j After the target amplification, the nucleic acids V 35 are ordinarily extracted and the amplified sequences WO 92/18650 PCr/US92/02983 WO 92/18650 PCT/US92/02983 7 are detected by the procedures set forth hereinabove.
It should be emphasized that the known procedures of the prior art are heterogeneous, that is, they require multiple steps in which the DNA is first hybridized to a signal generating probe, followed by a step in which the unhybridized probe is separated from hybridized probe. Ordinarily different sets of reagents are required for signal generation than for probe hybridization and separation. *A completely homogeneous method for detection of amplified nucleic acids without a separation step is unknown in the prior art.
Summary of the Invention In accordance with the present invention, nucleic acids amplified by any method are detected in a convenient homogeneous one-step method utilizing fluorescence polarization. The method of this invention comprises incubation of denatured amplified nucleic acids under hybridizing conditions with a nucleic acid probe of homologous sequence covalently coupled to a fluorophor. The fluorophor-conjugated probe is added at a concentration sufficient to produce a measurable increase in fluorescence polarization when hybridized to the amplified nucleic acid sequences, but not in an excess quantity so as to appreciably quench the increase in fluorescence polarization attributable to hybridization.
It will be apparent that the method of the present invention is adaptable to a simple automated format for convenient processing of a large number of samples.
This is because there is no nucleic acid extraction step, and it is unnecessary to separate unhybridized probe from the mixture. Further, the increase in fluorescence polarization upon hybridization is virtually instantaneous, and no repetitious shifts in ^A L -A i 1- )S p -i WO 92/18650 PCT/US92/02983 temperature are required in practicing the present method.
More particularly, the method of the invention comprises: a) Heating or otherwise denaturing a liquid mixture and for a length of time sufficient to separate duplex nucleic acids into single strands, b) adding a fluorochrome-conjugated nucleic acid probe having a base sequence complementary to a target sequence contained in the amplified nucleic mixture, c) lowering the temperature of the mixture or adjusting the pH to permit hybridization of probe sequences to amplified nucleic acids target sequences; d) incubating the mixture for a time sufficient for substantially complete hybridization to occur; and e) measuring the degree of fluorescence polarization.
In a preferred method, target nucleic acid sequences are incubated under hybridization conditions with a fluorescein-conjugated probe comprising an oligonucleotide having substantial complementarity to the-target nucleic acid sequences, the fluorescein being amino-linked to the oligonucleotide probe through an aminochlorotriazinylaminoalkylphosphoryl group, incubating for a time sufficient to obtain substantially complete hybridization, and measuring the fluorescence polarization. Probes for detecting a target nucleic acid sequence are also disclosed which comprise a fluorescein-conjugated oligonucleotide sequence of substantial complementarity to the target nucleic acid sequence, the fluorescein molecule being amino-linked to the oligonucleotide portion through an aminochlorotriazinylaminoalkylphosphoryl group. Most preferred probes are selected from the group. The meathod of cl-a.im 4 wherein the said probes are selected from the group consisting of oligonucleotides 35 substantially homologous to target nucleic acids 1\ -I .1, containing a guanosine or cytosine base in the position immediately 5' of the base annealing to the fluorescein-labelled terminal nucleotide of the said probe.
A kit is also contemplated by this invention, comprising a vessel containing a concentrated buffer solution of a composition optimizing hybridization of nucleic acids but without interfering with the measurement of fluorescence polarization, and a second vessel containing a solution of one or a plurality of nucleic acid probes conjugated to one or a plurality of assays. The solutions of the kit of this invention are readily deliverable step-wise to a multiplicity of sample containers. The samples can be processed through each of the method steps without transferring to another container, so that the incubations and fluorescence polarization determination can be accomplished in the same vessel and same machine under automation.
Detailed Description of the Preferred Embodiment In the technique of fluorescence polarization, light from a source is utilized to excite fluorescence emission from a fluorochrome molecule. A fluorophor or fluorochrome is a molecular entity, usually of molecular weight less than 10,000 daltons which emits fluorescent light at a characteristic wavelength when impacted with a radiant energy source. The fluorochrome is covalently coupled to a nucleic acid probe hybridizable with a complementary target S 30 amplified nucleic acid sequence. A variety of fluorochromes are known in the art which are adaptable Sto the present invention, including fluorescein derivatives, acidine orange (Van Bertalanffy et al., J.
Histochem. Cytochem., 4:481 (1956)), benzimidazole derivatives (Hilwig et al., Exp. Cell Res., 75:122, K rf -23- I: I; L~.iiiii__i WO 92/18650 PCr/US92/02983 1972)), and a series of fluorescent nucleic acid stains, as disclosed in U.S. Patent No. 4,544, 546. In addition, oligonucleotides bonded to DNA intercalating agents have been utilized as nucleic acid probes, as disclosed in U.S. Patent No. 4,835,263.
In the preferred embodiment, flucrescein is covalently attached to an oligonucleotide probe through an aminochlorotriazinylaminoalkyphosphoryl group having the generalized structure: Oligonucleotide
N
0 wherein n is an integer from 2 to about 12 (hereinafter referred to as DTAF). Most preferred is the fluorescein conjugted oligonucleotide amino-linked through an aminochlorotriazinylaminoethylphosphoryl group. It has been determined empirically that compounds of the preferred generalized structure are superior in generating signal than other amino-linker configurations, such as carboxy-fluorescein succinimidyl ester or the fluorescein isothiocyanate derivative (FITC) having the structure: 300 o Applicants have further discovered that detection of hybridization by fluorescence polarization is substantially enhanced in the preferred DTAF conjugated probe when the target sequence selected contains a WO 92/18650 PCT/US92/02983 11 guanosine or a cytosine base in the position immediately 5' of the base annealing to the fluorescein-labelled terminal nucleotide of the probe.
The oligonucleotide portion of the probe has a sequence of substantial complementarity to the amplified target nucleic acids, so that a duplex between probe and target is formed. It is apparent that perfect complementarity is not necessary so long as a stable duplex is formed under the hybridization conditions utilized, and that some base mismatching may be tolerated. It is further apparent that these probes may be used in the detection of any substantially homologous target nucleic acid sequence, and is not limited to detection of only amplified nucleic acid.
The principle of this technique is based upon the characteristic rotational properties of molecules in solution. Molecules have a tendency to tumbe about their various axes of rotation. In general, larger molecules tumbe more slowly than smaller ones.
Compared to the amplified DNA target molecules, the oligonucleotide fluorochrome-conjugated probes tumbe very rapidly and along several axes of rotation.
fluorescent light emitted from such spinning molecules is diffuse and characteristically multiplanar.
However, when the probe molecule has annealed to the target sequence forming a substantially rigid structure of high molecular weight, it loses much of its spin.
1 As a result fluorescence emission becomes relatively polarized. The emission fluorescence polarization of solution in which intercalating fluorochrome binds iwth DNA was described by Arschine et al., The EMBO 3, 795 (1984). This polarization effect can be measured conveniently in a fluorometer and a polarizatin value is calculated accordingly to the following equation: l' WO 92/18650 PCT/US92/02983 12 P IpA IpE IpA IPE wherein P is polarization units, IpA is the parallel intensity and IpE is the perpendicular intensity.
The oligonucleotide portions of the probe may have a variable number of bases, preferably about 10-40 which are substantially homologous with the target sequence. For generic identifications, it is important to sclect highly conserved regions of the genome so as to ensure substantial homology between different species, or genetic variants of the same infectious organu.m or other nucleic acid target. Further increased sensitivity of the present method may be attained by(sue of more than one probe specific for different amplified sequences. In the case of HIV, selection of conserved sequences is an important consideration because the envelope proteins-are genetically labile and mutant variations occur extremely rapidly. This has been found to result from replication errors. Reverse transcriptase is a highly imprecise replicator. On the other hand, since this property of the enzyme is particularly functional, the sequence encoding the enzyme itself is highly conserved. Accordingly, the sequences encoding the reverse transcriptase make excellent oligonucleotide probes which can be expected to hybridize to virtually any HIV variant. Conversely, selection of probes of short hybridizable sequences, preferable of 6 to 12 bases, from highly mutogeneic genomic regions may be utilized diagnostically to assess the degree of drift in homology over a period of time, or between different patient hosts.
As indicated hereinabove, there are now a number of different methods for amplifying nucleic acids.
WO 92/18650 pCr/US92/02983 i 1 1 J WO 92/18650 PCTUS92/02983 3/8 Once amplification has occurred, whether by PCR. TAS, 3SR, or LAS, the method of the present invention is equally applicable t detection of the nucleic acid so amplified, without regard to the amplification method used. It will be apparent to those skilled in the art that the inventive method of detection will be applicable as well to any future improvement or new technology in the nucleic acid amplification art.
The buffer utilized during hybridization may be selected from the group of buffers having buffering agents with a pH in the range of 6.5 to 8, having an ionic strength of 100 500 mM, and having 10 to 100 mM of a chelating substance. A typical buffer concentration) is described in Maniatis et al., Molecular Cloning, 1982 and contains 200 mM sodium monobasic phosphate, 3 M sodium chloride, 20 mM ethylene diamnetetracetic acid, at pH 7.4 It was found empirically that this buffer provides good conditions for hybridization without appreciable quenching or other deleterous effect on the fluorescence polarization detection step.
The kit of the present invention provides a first vessel in which amplification of specific nucleic acid is done in a small volume. The amplified nucleic acid is then denatured by boiling or by the addition of sodium hydroxide. A second vessel of the kit contains the probe in reconstitutable, lyopholozed, or j concentrated liquid form which also contains Shybridization buffer. The second vessel of the kit is made of a substance which does not readily absorb oligonucleotide molecules to its surfaces. Examples of such materials are polyethylene, polypropylene, teflon, silanized or siliconized glass. Finally, the opening of the vessels may have flange or valve means whereby S 35 to facilitate drawing of liquids contained therein into WO 92/18650 PCT/US92/02983 4/8 lines conveying the liquids to an automated machine for processing of a large number of amplified nucleic acid samples. Other advantages of the present invention will be apparent from the Examples which follow.
Examples In initial experiments, the target sequence selected for study was a section of the HIVPV22 sequence partially encoding reverse transcriptase of HIV. A section of this sequence (bases 1195-2690) was cloned into plasmid p24L utilizing conventional techniques. The PCR reactions on both the plasmid and DNA from infected cells, termed HIV-DASH amplification region. The oligonucleotide primers at the 3' and termini are shown on the figure. Upon denaturation of HIV-DASH and annealing of the primers to their target sequences, DNA polymerase, preferably a highly purified form of recombinant enzyme from which the endonuclease encoding sequences have been deleted, is added to obtain chain extension. This procedure was repeated several times. This method of PCR amplification does not depart appreciably from the method disclosed in U.S. Patent Nos. 4,683,145 and 4,683,202, and variations reported in the literature.
Upon completion of amplification,the nucleic acids are once again denatured. Denaturation can be effected thermally by boiling or, preferably, by addition of NaOH at 55 0 C resulting in a pH of approximately 13.
The fluorochrome-conjugated oligonucleotide probes are added. If denaturation was effected by boiling, renaturation will proceed by simply lowering the temperature to 370 48 0 C. If denaturation was effected at high pH, then a sufficient amount of Tris SpH 5.5 buffer is added to reduce the pH to 8, so that hybridization of probe proceeds.
7 2 WO 92/18650 PCT/US92/02983 5/8 Empirically, it was discovered that signal detection is enhanced when complementary probe pairs are employed, and also when more than one target sequence is used. AP.so, it was found that surprisingly a much better detection signal was generated in relatively large volumes of low target DNA concentration. Accordingly, the experiments of these examples were conducted in 1.5 2.0 ml volumes instead of 50 microliter microassays.
In the experiment of Example 1, reagents comprised a probe designated DASH3-AMI-FITC which has the oligonucleotide sequence shown in Figure 2, covalently attached through an amide linkage to fluorescein isothiocyanate designated DASH3, and a second unconjugated oligonucleotide sequence complementary to DASH3-AMI-FITC, designated DASHIC, and a third unconjugated oligonucleotide sequence, designated DASH#, as a noncomplementary control. These reagents were added together as follows: with 1.9 ml 5x SSPE buffer (750 mM NaCl, 10 mM sodium phosphate monobasic, 1 mM EDTA), 100 microliters 120 mM DASH3-AMI-FITC in SSPE buffer, 5, 20, 50, 100 microliters respectively, in separate tubes; 100 mM DASH3c in 5x SSPE buff-r, or alternatively, 5, 20, 50, 100 microliters 100 mM DASH3 in 5x SSPE, respectively in separate tubes. Background I fluorescence polarization values were obtained for each tube immediately after addition of the DASH3-AMI-FITC and before addition of the other probes. After the hybridization reactions were begun, fluorescence polarization was monitored over a 35 minute period.
The results are shown in Figure 3 of the drawings.
It is readily apparent that hybridization of the fluorochrome-conjugated probe with its complementary S_ probe sequence produces substantial polarization of fluorescence, and that the amount of polarization is S I WO 92/18650 PCT/US92/02983 6/8 WO 92/18650 PCT/US92/02983 16 substantially quantitative. This is essentially a control experiment demonstrating that hybridization to the relatively short complementary sequence brings about a significant degree of molecular spin inhibition.
Example 2 In another experiment, of substantially identical format, the capture target sequence for labelled probe is a PCR amplified HIV target derived from amplification of the p24L plasmid known to contain the DASH sequence. The results are shown in Figure 4 of the drawings. Hybridization was monitored over minutes and carried not in a total reaction volume of 1.6 ml. The glossary of graph points on the right side of the figure expresses the DNA content of the reaction mix as the number of tipomoles of pre-PCR DNA present prior to the amplification step and, correspond to 0, 102, 103, 104, and 105 pre-amplification molecules of p24L plasmid DNA. Denaturation was carried out by incubating 20 microliters PCR r.eaction mix with microliters water and 5 microliters NaOH at 55 0 C for minutes. Tubes containing 1.5 ml 5x SSPE buffer, 7 microliters of 3.2 M Tris-Hcl and 100 microliters DASH3-AMI-FITC (10 mM in 5x SSPE buffer) were prepared and background fluorescence polarization measured.
Fifty microliter aliquots of the PCR-DNAs were added and fluorescence polarization measured at the times indicated.
The results graphed in Figure 4 of the drawings clearly show an increase in fluorescence polarization which is generally dose-dependent with increasing amounts of added PCR-DNA. This is an especially significant finding because of the large excess of DNA present which is noncomplementary to the DASH sequence in this homogeneous assay.
WO 92/18650 PCT/US92/02983 17 Example 3 In a still further experiment the RNA fraction of H-9 cells infected with HIV virus was extracted by conventional methods. A portion containing 0.1 attomoles of HIV RNA was then amplified utilizing the 3SR amplification techniques described hereinabove.
Test tubes for assay of probe-RNA hybrids were prepared by adding 1.5 ml 5x SSPE buffer to 100 microliters of a mM DASH3-AMI-FITC solution. 3SR RNA was alkalie denatured. Sixty microliters of the denatured 3SR amplified RNA was added to the test tubes, and fluorescence polarization was monitored over a minute time period. The results, shown in Figure indicate that 3SR amplified RNA derived from the RNA fraction of HIV infected cells gives a strong, unequivocal positive signal compared to an unamplified control. This example illustrates that the detection method of the present invention is a versatile assay of nucleic acids containing target sequences amplified by any method.
Example 4 In the experiment of this example, the resolving power of the present method was evaluated. The supernatant from a growing culture of H-9 cells infected with HIV was obtained and the DNA putatively contained therein was subjected to 60 cycles of PRC.
The amounts of supernatant amplified corresponded to a volume of cultured cells containing 102, 103, 104 cells. Similarly, identical control supernatants were prepared from growing cultures of non-infected H-9 cells. Test tubes were prepared containing 1.5 ml SSPE buffer, 5 microliters IN NaOH, 7 microliters 3.2 M Tris pH 5.5, and 100 microliters of 10 mM DASH3-AMI- FITC. Target DNA was denatured by adding 5 microliters IN NaOH and, 25 microliters water to 20 microliters PCR WO 92/18650 PCT/US92/02983
AR/A
reaction mix followed by incubation at 55 0 C for minutes. Fifty microliters of the denatured PCR reaction solution was added to the test tubes containing the DASH3-AMI-FITC probe and hybridization proceeded with monitoring by fluorescence polarization.
Figure 6, shows that affirmative HIV sequence detection can be obtained of the PCR amplification of the supernatant containing as few as 200 cells. This means that the method of the present invention has sufficient sensitivity and resolving power to be useful as a routine serum screening assay for individuals with very early pre-clinical HIV infection.
In practicing the present invention, it must be emphasized that the probe technology and hybridization conditions are critical. The target sequences must have high binding affinity to probe and be highly specific for host sequences. Purity is Llso an important factor. Also, the fluorochrome-conjugated probe sequence length must be short enough that the rotational and relaxational properties show contrast in fluoroscence polarization values when hybridized.
Specific probe sequence may influence the rate at which annealing of probe to target sequence occurs, compared to the rate at which reannealing of native complementary target regions occurs. While is does appear that the amino-linker probe coupling strategy utilized in these examples is particularly efficacious, other linkage modes may theoretically be substituted by trial and error.
Example In these experiments the probe and target reagents were as follows: a probe designated DASH3-15-AMI-FITC which has the oligonucleotide sequence shown in Figure 7 covalently attached through an amino-linker arm to fluorescein isothiocyanate, a second probe designated INTERNATIONAL SEARCH REPORT sac.icational appliction No.
PCT/US92/02983 A. CLASSIFICATION OF SUBJECT MATTER IPC(S) :C12Q 1/68; C07H 15/12; C12N 15/00 US CL :435/6; 536/27; 935/77,78 WO 92/18650 PCT/US92/02983 19 DASH3-15-AMI-DTAF whch has an identical sequence as the above probe but covalently attached through an aminolinker arm to dichlorotrianzinylaminofluorescein, and an unconjugated oligonucleotide target sequence designated T23-DASHIC which has the sequence shown in Figure 7 and which is complementary to both of the above probes. In separate tubes each probe was added to the target sequence and fluorescence polarization was monitor as in Example 2. The results tabulated in Table 1 clearly shown that upon hybridization to a complementary target sequence, a probe labelled with DTAF gives higher changes in fluorescence polarization (delta mP) than a probe labelled with FITC, upon hybridization to a complementary target sequence.
Table 1 FLUORESCENCE POLARIZATION (mP) Pre- Post- PROBE hybridization hybridization Delta 93.0 169.8 76.8 DASH-15-AMI-DTAF 111.8 240.1 128.3 In further experiments the probe and target were as follows: a probe designated DASH3-15-AMI-DTAF which has the oligonucleotide sequence shown in Figure 8 covalently attached through an amino-linker arm to dichlorotrianzinylaminofluorescein, and five unconjugated oligonucleotide target sequence designated T23-DASHIC-G, T23-DASHIC-A, T23-DASHIC-T, and T23- DASHIC-C which have the sequences shown in Figure 8 and are complementary to the above probe. In separate tubes the probe was added to each of target sequences and fluorescence polarization was monitored as in Example 2. The results, graphed in Figure 9 clearly, shows that the nucleotide of target sequence adjacent to the probes' linker arm after the hybridization affects the degree of fluorescence polarization.
WO 92/18650 PCT/US92/02983 Greater changes (delta ml') in fluorescence polarization are obtained if the said nucleotide is a deoxycytidine or a deoxyguariidine
Claims (14)
1. The method of detecting amplified nucleic acids comprising: a) incubating denatured amplified nucleic acids with a fluorochrome-coupled nucleic acid probe of complementary base sequence, whereby to hybridize said amplified nucleic acids to said probe, and b) measuring the fluorescence polarization of said hybridized nucleic acids and probe.
2. The method of detecting amplified nucleic acids comprising: a) denaturing a liquid mixture containing amplified nucleic acids, by heating to a temperature and for a length of time sufficient to separate duplex nucleic acids into single strands; b) adding a fluorochrome-conjugated nucleic acid probe having a base sequence complementary to a target sequence contained in the amplified nucleic mixture; c) lowering the temperature; d) incubating the mixture for a time sufficient for substantially complete hybridization to occur; and e) measuring the degree of fluorescence polarization.
3. The method of detecting amplified nucleic acids comprising: a) denaturing a liquid mixture containing amplified nucleic acids by raising the pH; b) adding a fluorochrome-conjugated nucleic acid probe having a base sequence complementary to a target sequence contained in the amplified nucleic mixture; I WO 92/18650 PCT/US92/02983 22 c) adjusting the pH to permit hybridization of probe sequences to amplified nucleic acids target sequences; d)incubating the mixture for a time sufficient for substantially complete hybridization to occur; and e) measuring the degree of fluorescence polarization.
4. The method of claim 1, 2, or 3, wherein said probe oligonucleotide contains 8 to 40 bases.
The method of detecting amplified target nucleic acids comprising: incubating amplified nucleic acids with a fluorescein-conjugated oligonucleotide probe having a sequence of substantial complementarity to the said target nucleic acids, said fluorescein being amino-linked to said probe through an aminochlorotriazin' laminoalkylphosphoryl group incubating for a time sufficient for substantially complete hybridization to occur; and measuring the degree of fluorescence polarization.
6. The method of claim 4 wherein the said probes are selected from the group consisting of oligonucleotides substantially homologous to target nucleic acids contianing a guanosine or cytosine base in the position immediately 5' of the base annealing to the fluorescein-labelled terminal nucleotide of the said probe.
7. A probe for detecting a target nucleic acid sequence comprising a fluorescein-conjugated oligonucleotide having a sequence of substantial complementarity to the said target nucleic acid sequence, said Sfluorescein being amino-linked to said probe I 1 -23- through an aminochlorotriazinylaminoalkylphosphoryl group.
8. The probe of claim 6 wherein said probes are selected from the group consisting of oligonucleotides substantially homologous to target nucleic acids containing a guanosine or cytosine base in the position immediately 5' of the base annealing to the fluorescein-labelled terminal nucleotide of the said probe.
9. The method of claim 1, 2, or 3, wherein said probe oli.onucleotide sequence is derived from the HIV genome sequence encoding reverse transcriptase.
10. The method of claim 1, 2, or 3, wherein said amplified nucleic acids were amplified by the PCR technique.
11. The method of claim 1, 2, or 3, wherein said amplified nucleic acids were amplified by the TAS technique.
12. The method of claim 1, 2, or 3, wherein said amplified nucleic acids were amplified by the 3SR technique.
13. The method of claim 1, 2, or 3, wherein said amplified nucleic acids were amplified by the LAS technique.
14. A kit when used according to the method of claim 1, for detecting amplified nucleic acids comprising: a first vessel containing a hybridization buffer, and a second vessel containing a fluorochrome-coupled oligonucleotide probe. Dated this 25th day of July, 1994. BAXTER DIAGNOSTICS INC. Patent Attorneys for the Applicant A, PETER MAXWELL ASSOCIATES
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68392391A | 1991-04-11 | 1991-04-11 | |
| US683923 | 1991-04-11 | ||
| PCT/US1992/002983 WO1992018650A1 (en) | 1991-04-11 | 1992-04-10 | Detection of dna/rna by fluorescence polarization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU1690492A AU1690492A (en) | 1992-11-17 |
| AU656965B2 true AU656965B2 (en) | 1995-02-23 |
Family
ID=24746024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU16904/92A Ceased AU656965B2 (en) | 1991-04-11 | 1992-04-10 | Detection of DNA/RNA by fluorescence polarization |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0533906A4 (en) |
| JP (1) | JPH05508323A (en) |
| AU (1) | AU656965B2 (en) |
| CA (1) | CA2084405A1 (en) |
| WO (1) | WO1992018650A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641629A (en) * | 1990-06-11 | 1997-06-24 | Nexstar Pharmacueticals Inc | Spectroscopically detectable nucleic acid ligands |
| US5547861A (en) | 1994-04-18 | 1996-08-20 | Becton, Dickinson And Company | Detection of nucleic acid amplification |
| CA2145719C (en) * | 1994-04-18 | 1998-06-30 | James G. Nadeau | Detection of nucleic acid amplification |
| DE4418691A1 (en) * | 1994-05-28 | 1996-02-22 | Boehringer Mannheim Gmbh | 3 '- (4'-) non-radioactively labeled nucleosides and nucleotides with amino carboxylic acid, peptide or carboxylic acid spacer |
| US5786139A (en) * | 1994-12-09 | 1998-07-28 | Panvera Corporation | Method and kit for detecting nucleic acid cleavage utilizing a covalently attached fluorescent tag |
| US5800989A (en) * | 1995-11-15 | 1998-09-01 | Becton, Dickinson And Company | Method for detection of nucleic acid targets by amplification and fluorescence polarization |
| US5641633A (en) * | 1995-11-15 | 1997-06-24 | Becton, Dickinson And Company | Fluorescence polarization detection of nucleic acids |
| CA2190430A1 (en) * | 1995-12-12 | 1997-06-13 | Margret Barbara Basinski | Method for measuring genetic messages |
| US5888736A (en) * | 1995-12-22 | 1999-03-30 | Visible Genetics, Inc. | Method, compositions and kit for detection and identification of microorganisms |
| US6413718B1 (en) | 1996-05-01 | 2002-07-02 | Visible Genetics Inc. | Method for sequencing of nucleic acid polymers |
| US6451530B1 (en) | 1996-12-13 | 2002-09-17 | The United States Of America As Represented By The Department Of Health And Human Services | Fluorescent nucleotide analog hairpin formation for detection of nucleic acid hybridization |
| US6060242A (en) * | 1997-02-27 | 2000-05-09 | Lorne Park Research, Inc. | PNA diagnostic methods |
| US6251591B1 (en) | 1997-02-27 | 2001-06-26 | Lorne Park Research, Inc. | Quantitative method for detecting nucleotide concentration |
| US6046004A (en) * | 1997-02-27 | 2000-04-04 | Lorne Park Research, Inc. | Solution hybridization of nucleic acids with antisense probes having modified backbones |
| WO1998038334A1 (en) * | 1997-02-27 | 1998-09-03 | Lorne Park Research, Inc. | Assaying nucleotides in solution using pna probes |
| US5846729A (en) * | 1997-02-27 | 1998-12-08 | Lorne Park Research, Inc. | Assaying nucleotides in solution using a fluorescent intensity quenching effect |
| US6503709B1 (en) | 1997-07-03 | 2003-01-07 | Id Biomedical Corporation | Methods for rapidly detecting methicillin resistant staphylococci |
| US6255050B1 (en) | 1998-05-22 | 2001-07-03 | Lorne Park Research, Inc. | Dynamic hybridization system |
| US6645733B1 (en) | 1999-06-25 | 2003-11-11 | Ingeneus Corporation | Fluorescent intensity method for assaying binding between proteins or peptides |
| EP1715063B1 (en) * | 2000-03-29 | 2011-01-26 | LGC Limited | Hybridisation beacon and method of rapid sequence detection and discrimination |
| WO2002046453A2 (en) * | 2000-12-05 | 2002-06-13 | Syngenta Participations Ag | Method and kit for identification of nucleic acid modification enzymes and inhibitors thereof |
| US7222059B2 (en) | 2001-11-15 | 2007-05-22 | Siemens Medical Solutions Diagnostics | Electrophoretic trace simulator |
| US6589744B2 (en) | 2001-11-26 | 2003-07-08 | Syngenta Participations Ag | Method and kit for identification for nucleic acid modification enzymes and inhibitors thereof |
| CN110305969B (en) * | 2019-07-17 | 2022-11-22 | 合肥工业大学 | Method for detection of adulterated meat components based on fluorescence polarization |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| AU7495591A (en) * | 1990-02-26 | 1991-09-18 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | A method for the fluorescent detection of a dna sequence in real time |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4820630A (en) * | 1984-11-23 | 1989-04-11 | Digene Diagnostics, Incorporated | Assay for nucleic acid sequences, particularly genetic lesions, using interactive labels |
| GB8902689D0 (en) * | 1989-02-07 | 1989-03-30 | Ici Plc | Assay method |
-
1992
- 1992-04-10 AU AU16904/92A patent/AU656965B2/en not_active Ceased
- 1992-04-10 CA CA002084405A patent/CA2084405A1/en not_active Abandoned
- 1992-04-10 JP JP4509397A patent/JPH05508323A/en active Pending
- 1992-04-10 EP EP9292910181A patent/EP0533906A4/en not_active Withdrawn
- 1992-04-10 WO PCT/US1992/002983 patent/WO1992018650A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683202B1 (en) * | 1985-03-28 | 1990-11-27 | Cetus Corp | |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683195B1 (en) * | 1986-01-30 | 1990-11-27 | Cetus Corp | |
| AU7495591A (en) * | 1990-02-26 | 1991-09-18 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | A method for the fluorescent detection of a dna sequence in real time |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1992018650A1 (en) | 1992-10-29 |
| AU1690492A (en) | 1992-11-17 |
| CA2084405A1 (en) | 1992-10-12 |
| EP0533906A4 (en) | 1994-09-28 |
| JPH05508323A (en) | 1993-11-25 |
| EP0533906A1 (en) | 1993-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU656965B2 (en) | Detection of DNA/RNA by fluorescence polarization | |
| KR0173133B1 (en) | Polynucleotide capture assay employing in vitro amplification | |
| JP3514630B2 (en) | Amplification and detection of nucleic acid sequences | |
| AU2010200419B2 (en) | Detection of herpes simplex virus types 1 and 2 by nucleic acid amplification | |
| EP0163220B1 (en) | Nucleic acid hybridization assay employing detectable anti-hybrid antibodies | |
| US5780227A (en) | Oligonucleotide probe conjugated to a purified hydrophilic alkaline phosphatase and uses thereof | |
| US5403707A (en) | Diagnostic compositions, elements, methods and test kits for amplification and detection of retroviral DNA using primers having matched melting temperatures | |
| EP0625211B1 (en) | Amplification of assay reporters by nucleic acid replication | |
| US6007984A (en) | Detection of DNA/RNA by fluorescence polarization | |
| JPH09503910A (en) | Oligonucleotides and methods for the detection of Trachoma chlamydia | |
| JP2001095590A (en) | Probes for nucleic acid hybridization assays | |
| US7105318B2 (en) | Specific and sensitive nucleic acid detection method | |
| JP4047395B2 (en) | Method for simultaneous amplification of nucleic acids | |
| EP0892856A1 (en) | A method for the amplification and detection of a nucleic acid fragment of interest | |
| JPH11502124A (en) | All-in-one nucleic acid amplification assay | |
| US10655190B2 (en) | Compositions and methods for detection of Zika virus | |
| DK160107B (en) | PROCEDURE FOR DETECTING A PARTICULAR SINGLE-STRUCTURED POLYNUCLEOTIDE SEQUENCE IN A TESTING MEDIUM CONTAINING SINGLE-STRUCTED NUCLEIC ACIDS AND REAGENT SYSTEM FOR USING THE PROCEDURE | |
| JPH06319597A (en) | Diagnostic composition, element and method and test kit for amplifying and detecting two or more dna having similar melting point | |
| JP5722521B2 (en) | Reagent and method for detecting gonococci | |
| KR100442196B1 (en) | Method for amplification and detection of target nucleic acid using postamplificationincubation step | |
| JPH0714359B2 (en) | Method for producing modified nucleic acid | |
| JP2000511777A (en) | Nucleic acid primers and probes for detecting Chlamydia pneumoniae | |
| JPH10505230A (en) | Methods for Amplifying Nucleic Acids Using Modified Nucleosides and Detection of Amplification Products Using Antibodies | |
| JP2982304B2 (en) | Method for identifying nucleic acid and test set for identifying nucleic acid | |
| NO844849L (en) | HYBRIDIZATION ANALYSIS USING LABELED COUPLES OF HYBRID BINDING REAGENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |